参考文献
1. Timothy R Rebbeck，Christine B Ambrosone，Peter G Shields.Molecular Epidemiology：Applications in Cancer and Other Human Diseases.New York：Informa Healthcare，2008.
2. Eichelbaum M，Ingelman-Sundberg M，Evans WE.Pharmacogenomics and individualized drug therapy.Annu Rev Med，2006，57：119-137.
3.刘宝瑞，钱晓萍.临床肿瘤学：基本理论与诊疗路径.北京：科学出版社，2007.
4. Berger MS，Gullick WJ，Greenfield C，et al.Epidermal growth factor receptors in lung tumours.J Pathol，1987，152 （4）：297-307.
5. Korpanty G，Smyth E，Sullivan LA，et al.Antiangiogenic therapy in lung cancer：focus on vascular endothelial growth factor pathway.Exp Biol Med（Maywood），2010，235（1）：3-9.
6. Zhukov NV，Tjulandin SA.Targeted therapy in the treatment of solid tumors：practice contradicts theory.Biochemistry（Mosc），2008，73（5）：605-618.
7. Mwenifumbo JC，Marra MA.Cancer genome-sequencing study design.Nat Rev Genet，2013，14（5）：321-332.
8. Dalton WS，Friend SH.Cancer biomarkers--an invitation to the table.Science，2006，312（5777）：1165-1168.
9. Ulrich CM，Robien K，McLeod HL. Cancer pharmacogenetics：polymorphisms，pathways and beyond. Nat Rev Cancer，2003，3（12）：912-920.
10. Popat S，Hubner R，Houlston RS.Systematic review of microsatellite instability and colorectal cancer prognosis.J Clin Oncol，2005，23（3）：609-618.
11. Amend K，Hicks D，Ambrosone CB.Breast cancer in African-American women：differences in tumor biology from European-American women.Cancer Res，2006，66（17）：8327-8330.
12. Ludwig JA，Weinstein JN.Biomarkers in cancer staging，prognosis and treatment selection.Nat Rev Cancer，2005，5（11）：845-856.
13. Kuehl P，Zhang J，Lin Y，et al.Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression.Nat Genet，2001，27（4）：383-391.
14. Anderer G，Schrappe M，Brechlin AM，et al.Polymorphisms within glutathione S-transferase genes and initial response to glucocorticoids in childhood acute lymphoblastic leukaemia.Pharmacogenetics，2000，10（8）：715-726.
15. Innocenti F，Ratain MJ.Update on pharmacogenetics in cancer chemotherapy.Eur J Cancer，2002，38（5）：639-644.
16. Ando Y，Saka H，Ando M，et al.Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity：apharmacogenetic analysis.Cancer Res，2000，60（24）：6921-6926.
17. Kawakami K，Omura K，Kanehira E，et al.Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers.Anticancer Res，1999，19（4B）：3249-3252.
18. Pullarkat ST，Stoehlmacher J，Ghaderi V，et al.Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy.Pharmacogenomics J，2001，1（1）：65-70.
19. Eichelbaum M，Fromm MF，Schwab M.Clinical aspects of the MDR1（ABCB1）gene polymorphism.Ther Drug Monit，2004，26（2）：180-185.
20. Mahadevan D，List AF.Targeting the multidrug resistance-1 transporter in AML：molecular regulation and therapeutic strategies.Blood，2004，104（7）：1940-1951.
21. Chang H，Rha SY，Jeung HC，et al.Association of the ABCB1 gene polymorphisms 2677G＞T/A and 3435C＞T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients.Ann Oncol，2009，20（2）：272-277.
22. Mathijssen RH，Marsh S，Karlsson MO，et al.Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin Cancer Res，2003，9（9）：3246-3253.
23. Giachino DF，Ghio P，Regazzoni S，et al.Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer.Clin Cancer Res，2007，13（10）：2876-2881.
24. Kalikaki A，Kanaki M，Vassalou H，et al.DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer.Clin Lung Cancer，2009，10（2）：118-123.
25. de las Peñas R，Sanchez-Ronco M，Alberola V，et al.Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients.Ann Oncol，2006，17（4）：668-675.
26. Sun X，Li F，Sun N，et al.Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.Lung Cancer，2009，65（2）：230-236.
27. Sreeja L，Syamala VS，Syamala V，et al.Prognostic importance of DNA repair gene polymorphisms of XRCC1 Arg399Gln and XPD Lys751Gln in lung cancer patients from India.J Cancer Res Clin Oncol，2008，134（6）：645-652.
28. Gurubhagavatula S，Liu G，Park S，et al.XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy.J Clin Oncol，2004，22（13）：2594-2601.
29. Petty WJ，Knight SN，Mosley L，et al.Apharmacogenomic study of docetaxel and gemcitabine for the initial treatment of advanced non-small cell lung cancer.J Thorac Oncol，2007，2（3）：197-202.
30. Yoon SM，Hong YC，Park HJ，et al.The polymorphism andhaplotypes of XRCC1 and survival of non-small-cell lung cancer after radiotherapy.Int J Radiat Oncol Biol Phys，2005，63（3）：885-891.
31. Hu Z，Shu Y，Chen Y，et al.Genetic polymorphisms in the precursor MicroRNA flanking region and non-small cell lung cancer survival.Am J Respir Crit Care Med，2011，183（5）：641-648.
32. Hu L，Wu C，Zhao X，et al.Genome-wide association study of prognosis in advanced non-small cell lung cancer patients receiving platinum-based chemotherapy.Clin Cancer Res，2012，18（19）：5507-5514.
33. Wu C，Li D，Jia W，et al.Genome-wide association study identifies common variants in SLC39A6 associated with length of survival in esophageal squamous-cell carcinoma.Nat Genet，2013，45（6）：632-638.
34. Stratton MR，Campbell PJ，Futreal PA.The cancer genome.Nature，2009，458（7239）：719-724.
35. Vogelstein B，Papadopoulos N，Velculescu VE，et al.Cancer genome landscapes.Science，2013，339（6127）：1546-1558.
36. Graziano SL，Gamble GP，Newman NB，et al.Prognostic significance of K-ras codon 12 mutations in patients with resected stageⅠandⅡnon-small-cell lung cancer.J Clin Oncol，1999，17（2）：668-675.
37. Meng D，Yuan M，Li X，et al.Prognostic value of K-RAS mutations in patients with non-small cell lung cancer：a systematic review with meta-analysis.Lung Cancer，2013，81（1）：1-10.
38. Eberhard DA，Johnson BE，Amler LC，et al.Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.J Clin Oncol，2005，23（25）：5900-5909.
39. Krause DS，VanEtten RA.Tyrosine kinases as targets for cancer therapy.N Engl J Med，2005，353（2）：172-187.
40. Paez JG，Jänne PA，Lee JC，et al.EGFR mutations in lung cancer：correlation with clinical response to gefitinib therapy.Science，2004，304（5676）：1497-1500.
41. Kim ES，Hirsh V，Mok T，et al.Gefitinib versus docetaxel in previously treated non-small-cell lung cancer（INTEREST）：a randomised phaseⅢtrial.Lancet，2008，372（9652）：1809-1818.
42. Mitsudomi T，Morita S，Yatabe Y，et al.Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor（WJTOG3405）：an open label，randomised phase 3 trial.Lancet Oncol，2010，11（2）：121-128.
43. Fukuoka M，Wu YL，Thongprasert S，et al.Biomarker analyses and final overall survival results from a phaseⅢ，randomized，open-label，first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia（IPASS）.J Clin Oncol，2011，29（21）：2866-2874.
44. Maemondo M，Inoue A，Kobayashi K，et al.North-East Japan Study Group.Gefitinib or chemotherapy for nonsmall-cell lung cancer with mutated EGFR.N Engl J Med，2010，362（25）：2380-2388.
45. Olivier M，Taniere P.Somatic mutations in cancer prognosis and prediction：lessons from TP53 and EGFR genes. Curr Opin Oncol，2011，23（1）：88-92.
46. Di Leo A，Tanner M，Desmedt C，et al.p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phaseⅢclinical trial. Ann Oncol，2007，18（6）：997-1003.
47. Chrisanthar R，Knappskog S，Løkkevik E，et al. CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer.PLoS One，2008，3（8）：e3062.
48. Marcus JN，Watson P，Page DL，et al.Hereditary breast cancer：pathobiology，prognosis，and BRCA1 and BRCA2 gene linkage.Cancer，1996，77（4）：697-709.
49. Gaffney DK，Brohet RM，Lewis CM，et al.Response to radiation therapy and prognosis in breast cancer patients with BRCA1 and BRCA2 mutations.Radiother Oncol，1998，47（2）：129-136.
50. Verhoog LC，Brekelmans CT，Seynaeve C，et al.Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1.Lancet，1998，351（9099）：316-321.
51. Brekelmans CT，Seynaeve C，Menke-Pluymers M，et al.Survival and prognostic factors in BRCA1-associated breast cancer.Ann Oncol，2006，17（3）：391-400.
52. Kriege M，Seynaeve C，Meijers-Heijboer H，et al.Distant disease-free interval，site of first relapse and post-relapse survival in BRCA1-and BRCA2-associated compared to sporadic breast cancer patients.Breast Cancer Res Treat，2008，111（2）：303-311.
53. Rennert G，Bisland-Naggan S，Barnett-Griness O，et al.Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations.N Engl J Med，2007，357（2）：115-123.
54. Bonadona V，Dussart-Moser S，Voirin N，et al. Prognosis of early-onset breast cancer based on BRCA1/2 mutation status in a French population-based cohort and review. Breast Cancer Res Treat，2007，101（2）：233-245.
55. Tuna M，Amos CI.Genomic sequencing in cancer.Cancer Lett，2013，340（2）：161-170.
56. Govindan R，Ding L，Griffith M，et al.Genomic landscape of non-small cell lung cancer in smokers and neversmokers.Cell，2012，150（6）：1121-1134.
57. Kan Z，Zheng H，Liu X，et al.Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma.Genome Res，2013，23（9）：1422-1433.
58. Yan XJ，Xu J，Gu ZH，et al.Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia.Nat Genet，2011，43（4）：309-315.
59. Song Y，Lin L，Ou Y，et al.Identification of genomic alterations in oesophageal squamous cell cancer.Nature，2014.doi：10.1038/nature13176.
60. Pils D，Horak P，Vanhara P，et al.Methylation status of TUSC3 is a prognostic factor in ovarian cancer.Cancer，2013，119（5）：946-954.
61. Ogino S，Meyerhardt JA，Kawasaki T，et al.CpG island methylation，response to combination chemotherapy，and patient survival in advanced microsatellite stable colorectal carcinoma.Virchows Arch，2007，450（5）：529-537.
62. Rettori MM，de Carvalho AC，Bomfim Longo AL，et al.Prognostic significance of TIMP3 hypermethylation in post-treatment salivary rinse from head and neck squamous cell carcinoma patients.Carcinogenesis，2013，34 （1）：20-27.
63. Grimminger PP，Maus MK，Schneider PM，et al.Glutathione S-transferase PI（GST-PI）mRNA expression and DNA methylation is involved in the pathogenesis and prognosis of NSCLC.Lung Cancer，2012，78（1）：87-91.
64. Palmieri C，Monteverde M，Lattanzio L，et al.Site-specific CpG methylation in the CCAAT/enhancer binding protein delta（CEBPδ）CpG island in breast cancer is associated with metastatic relapse.Br J Cancer，2012，107 （4）：732-738.
65. Lujambio A，Calin GA，Villanueva A，et al. A microRNA DNA methylation signature for human cancer metastasis.Proc Natl Acad Sci U S A，2008，105（36）：13556-13561.
66. Roman-Gomez J，Agirre X，Jiménez-Velasco A，et al.Epigenetic regulation of microRNAs in acute lymphoblastic leukemia.J Clin Oncol，2009，27（8）：1316-1322.
67. Simon GR，Sharma S，Cantor A，et al.ERCC1 expression is a predictor of survival inresected patients with nonsmall cell lung cancer.Chest，2005，127（3）：978-983.
68. Davidson JD，Ma L，Flagella M，et al.An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines.Cancer Res，2004，64（11）：3761-3766.
69. Olaussen KA，Dunant A，Fouret P，et al.DNA repair by ERCC1 in non-small-cell lung cancer and cisplatinbased adjuvant chemotherapy.N Engl J Med，2006，355（10）：983-991.
70. Pesta M，Kulda V，Fiala O，et al.Prognostic significance of ERCC1，RRM1 and BRCA1 in surgically-treated patients with non-small cell lung cancer.Anticancer Res，2012，32（11）：5003-5010.
71. Zheng Z，Chen T，Li X，et al.DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer.N Engl J Med，2007，356（8）：800-808.
72. Simon G，Sharma A，Li X，et al.Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer.J ClinOncol，2007，25（19）：2741-2746.
73. Williams GH，Stoeber K.The cell cycle and cancer.J Pathol，2012，226（2）：352-364.
74. D’Amico TA，Massey M，Herndon JE，et al.A biologic risk model for stage I lung cancer：immunohistochemical analysis of 408 patients with the use of ten molecular markers. J Thorac Cardiovasc Surg，1999，117（4）：736-743.
75. Shoji T，Tanaka F，Takata T，et al.Clinical significance of p21 expression in non-small-cell lung cancer.J Clin Oncol，2002，20（18）：3865-3871.
76. Hommura F，Dosaka-Akita H，Mishina T，et al.Prognostic significance of p27KIP1 protein and ki-67 growth fraction in non-small cell lung cancers.Clin Cancer Res，2000，6（10）：4073-4081.
77. González-Quevedo R，Iniesta P，Morán A，et al.Cooperative role of telomerase activity and p16 expression in the prognosis of non-small-cell lung cancer.J Clin Oncol，2002，20（1）：254-262.
78. Fukuse T，Hirata T，Naiki H，et al.Prognostic significance of cyclin E overexpression in resected non-small cell lung cancer.Cancer Res，2000，60（2）：242-244.
79. Mishina T，Dosaka-Akita H，Hommura F，et al.Cyclin E expression，a potential prognostic marker for non-small cell lung cancers.Clin Cancer Res，2000，6（1）：11-16.
80. Dobashi Y，Jiang SX，Shoji M，et al.Diversity in expression and prognostic significance of G1/S cyclins in human primary lung carcinomas.J Pathol，2003，199（2）：208-220.
81. Uramoto H，Osaki T，Inoue M，et al.Fas expression in non-small cell lung cancer：its prognostic effect in completely resected stageⅢpatients.Eur J Cancer，1999，35（10）：1462-1465.
82. Koomägi R，Volm M.Expression of Fas（CD95/APO-1）and Fas ligand in lung cancer，its prognostic and predictive relevance.Int J Cancer，1999，84（3）：239-243.
83. Silvestrini R，Costa A，Lequaglie C，et al.Bcl-2 protein and prognosis in patients with potentially curable nonsmall-cell lung cancer.Virchows Arch，1998，432（5）：441-444.
84. Cox G，Louise Jones J，Andi A，et al.Bcl-2 is an independent prognostic factor and adds to a biological model for predicting outcome in operable non-small cell lung cancer.Lung Cancer，2001，34（3）：417-426.
85. Ohsaki Y，Toyoshima E，Fujiuchi S，et al.bcl-2 and p53 protein expression in non-small cell lung cancers：correlation with survival time.Clin Cancer Res，1996，2（5）：9.
86. Kren L，Brazdil J，Hermanova M，et al.Prognostic significance of anti-apoptosis proteins survivin and bcl-2 in non-small cell lung carcinomas：a clinicopathologic study of 102 cases.Appl Immunohistochem Mol Morphol，2004，12（1）：44-49.
87. Oshita F，Ito H，Ikehara M，et al.Prognostic impact of survivin，cyclin D1，integrin beta1，and VEGF in patients with small adenocarcinoma of stage I lung cancer.Am J Clin Oncol，2004，27（4）：425-428.
88. Harpole DH Jr，Herndon JE，Wolfe WG，et al.A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation，histopathology，and oncoprotein expression.Cancer Res，1995，55（1）：51-56.
89. Kwiatkowski DJ，Harpole DH Jr，Godleski J，et al.Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients：clinical implications.J Clin Oncol，1998，16（7）：2468-2477.
90. Yanaihara N，Caplen N，Bowman E，et al.Unique microRNA molecular profiles in lung cancer diagnosis and prognosis.Cancer Cell，2006，9（3）：189-198.
91. Nasser MW，Datta J，Nuovo G，et al.Down-regulation of micro-RNA-1（miR-1）in lung cancer.Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1.J Biol Chem，2008，283（48）：33394-33405.
92. Su H，Yang JR，Xu T，et al.MicroRNA-101，down-regulated in hepatocellular carcinoma，promotes apoptosis and suppresses tumorigenicity.Cancer Res，2009，69（3）：1135-1142.
93. Mitchell PS，Parkin RK，Kroh EM，et al.Circulating microRNAs as stable blood-based markers for cancer detection.Proc Natl Acad Sci U S A，2008，105（30）：10513-10518.
94. Chen X，Ba Y，Ma L，et al.Characterization ofmicroRNAs in serum：a novel class of biomarkers for diagnosis of cancer and other diseases.Cell Res，2008，18（10）：997-1006.
95. Hu Z，Chen X，Zhao Y，et al.SerummicroRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer.J Clin Oncol，2010，28（10）：1721-1726.
96.曾益新，吕有勇，朱明华，等.肿瘤学.第2版.北京：人民卫生出版社，2003：11-30.
97. Cheng AL，Huang WG，Chen ZC，et al.Identificating cathepsin D as a biomarker for differentiation and prognosis of nasopharyngeal carcinoma by laser capture microdissection and proteomic analysis.J Proteome Res，2008，7 （6）：2415-2426.
98. Uemura N，Nakanishi Y，Kato H，et al.Transglutaminase 3 as a prognostic biomarker in esophageal cancer revealed by proteomics.Int J Cancer，2009，124（9）：2106-2115.
99. Ricolleau G，Charbonnel C，Lodé L，et al.Surface-enhanced laser desorption/ionization time of flight mass spectrometry protein profiling identifies ubiquitin and ferritin light chain as prognostic biomarkers in node-negative breast cancer tumors.Proteomics，2006，6（6）：1963-1975.
100. Liu YF，Xiao ZQ，Li MX，et al.Quantitative proteome analysis reveals annexin A3 as a novel biomarker in lung adenocarcinoma.J Pathol，2009，217（1）：54-64.
101. Hodgkinson VC，Eagle GL，Drew PJ，et al.Biomarkers of chemotherapy resistance in breast cancer identified by proteomics：current status.Cancer Lett，2010，294（1）：13-24.
102. Hughes B，Yip D，Goldstein D，et al.Cerebral relapse of metastatic gastrointestinal stromal tumor during treatment withimatinib mesylate：case report.BMC Cancer，2004，4：74.
103. Serkova N，Boros LG.Detection of resistance to imatinib by metabolic profiling：clinical and drug development implications.Am J Pharmacogenomics，2005，5（5）：293-302.
104. Weiss L，Hufnagl C，Greil R.Circulating tumor DNA to monitor metastatic breast cancer.N Engl J Med，2013，369（1）：93.